COLLEGIUM PHARMACEUTICAL, INC — Form 8-K
Filed October 19, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Collegium Pharmaceutical terminated a material definitive agreement effective October 15, 2026. The 8-K filing does not specify the counterparty, dollar amounts, financial terms, or business impact of the termination. Only the item code (1.02) and date are disclosed in this document stub.
Why this rating
Agreement termination is material-designation procedural disclosure; specifics absent. Scale-relative impact cannot be assessed without counterparty identity and terms.
Extracted items
- 1.02 agreement termination
See more from October 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.